Human Immunology News Volume 11.22 | Jun 6 2023

    By
    Bob
    -
    0
    16








    2023-06-06 | HIN 11.22


    Human Immunology News by STEMCELL Technologies
    Vol. 11.22 – 6 June, 2023
    TOP STORY

    Human Skin-Resident CD8+ T Cells Require RUNX2 and RUNX3 for Induction of Cytotoxicity and Expression of the Integrin CD49a

    The authors demonstrated the enrichment of RUNT family transcription-factor-binding motifs in human epidermal CD8+CD103+CD49a+ TRM cells, paralleled by high RUNX2 and RUNX3 protein expression.
    [Immunity]

    AbstractGraphical Abstract
    Animal Origin-Free cGMP HSPC Expansion Media
    PUBLICATIONSRanked by the impact factor of the journal

    IgA Deficiency Destabilizes Homeostasis Toward Intestinal Microbes and Increases Systemic Immune Dysregulation

    Researchers developed an integrated host-commensal approach combining microbial flow cytometry and metagenomic sequencing to comprehensively define which microbes induced mucosal and systemic antibodies.
    [Science Immunology]

    Abstract

    Functional Binding of PD1 Ligands Predicts Response to Anti-PD1 Treatment in Patients with Cancer

    The authors presented a new concept for a bioassay to predict the response to anti-PD1 therapies, which was based on measuring the binding functionality of PDL1 and PDL2 to their receptor, PD1.
    [Science Advances]

    Full ArticlePress Release

    A Non-Genetic Engineering Platform for Rapidly Generating and Expanding Cancer-Specific Armed T Cells

    Investigators developed a non-genetic engineering technology for rapidly manufacturing a large amount of cancer-specific T cells by utilizing a unique anti-cancer/anti-CD3 bispecific antibody to directly culture human peripheral blood mononuclear cells.
    [Journal of Biomedical Science]

    Full Article

    Pyruvate Metabolism Controls Chromatin Remodeling During CD4+ T Cell Activation

    Histone modification, transcriptomic, and carbon tracing analyses of pyruvate dehydrogenase (PDH)-deficient T cells showed PDH-dependent acetyl-CoA generation as a rate-limiting step during T activation.
    [Cell Reports]

    Full ArticleGraphical Abstract

    PTPN22 R620W Gene Editing in T Cells Enhances Low-Avidity TCR Responses

    Scientists utilized Crispr/Cas9 gene editing with donor DNA repair templates in human cord blood-derived, naive T cells to generate PTPN22 risk edited, non-risk edited, or knockout T cells from the same donor.
    [elife]

    Full ArticlePress Release

    An FC-Muted Bispecific Antibody Targeting PD-L1 and 4–1BB Induces Antitumor Immune Activity in Colorectal Cancer without Systemic Toxicity

    Humanized mice bearing human PD-L1-expressing MC38 or CT26 tumor transplants were established to assess the in vivo antitumor activity of HK010.
    [Cellular & Molecular Biology Letters]

    Full Article

    Uptake of Long-Chain Fatty Acids from the Bone Marrow Suppresses CD8+ T Cell Metabolism and Function in Multiple Myeloma

    Scientists observed that bone marrow CD8+ T cell function was decreased in multiplate myeloma patients compared to controls, and also was consistently lower within bone marrow samples than matched peripheral blood.
    [Blood Advances]

    Abstract

    Differing Natural Killer Cell, T Cell, and Antibody Profiles in Antiretroviral-Naive HIV-1 Viraemic Controllers with and without Protective HLA Alleles

    Researchers aimed to gain insight into potential mechanisms of control in protective human leukocyte antigen class I alleles (VC+) and controllers without protective alleles (VC-). They studied 15 VC+, 12 VC- and four healthy uninfected individuals
    [PLOS One]

    Full Article

    Image of erythroblasts which were simply & efficiently generated from PSCs using the STEMdiff Erythroid Kit.
    REVIEWS

    Biophysical and Mechanobiological Considerations for T Cell-Based Immunotherapy

    The authors focus on leveraging advances in immune biophysics and mechanobiology toward improving chimeric antigen receptor T-cell and anti-programmed cell death protein 1 therapies.
    [Trends In Pharmacological Sciences]

    Full Article
    INDUSTRY AND POLICY NEWS

    Precigen Receives FDA Clearance of IND to Initiate Phase II Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer

    The Phase II randomized, open-label, two-arm, multicenter study will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab versus pembrolizumab monotherapy in patients with recurrent or metastatic cervical cancer who are pembrolizumab resistant.
    [Precigen, Inc.]

    Press Release
    FEATURED EVENT

    Pulmonary Hypertension: State of the Art and Therapeutic Opportunities

    June 25 – 28, 2023
    Santa Fe, New Mexico, United States

    > See All Events

    JOB OPPORTUNITIES

    Research Assistant Professor – Obstetrics and Gynecology

    University of Pennsylvania – Philadelphia, Pennsylvania, United States

    Postdoctoral Fellow – Immuno-Oncology Research

    Salk Institute – La Jolla, California, United States

    Postdoctoral Fellow – Anti-Tumor Immunity & Melanoma Biology

    MD Anderson Cancer Center – Houston, Texas, United States

    Professor – Translational Immunology

    Karolinska Institutet – Solna, Sweden

    Postdoctoral Position – Prostate Immunology

    Eastern Virginia Medical School – Norfolk, Virginia, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Human Immunology News Twitter